|
|
| (445 intermediate revisions by 10 users not shown) |
| Line 1: |
Line 1: |
| {| class="wikitable" | | {{#ask: [[Is DrugClass::Benzodiazepine]] | ?SeizureDose=Dose | ?BrandName=Trade Name}} |
| | align="center" style="background:#f0f0f0;"|'''Medication''' | | |
| | align="center" style="background:#f0f0f0;"|'''Dose''' | | [[Scarlet_fever_1.2.jpg|thumb|"Slapped cheeks" and "white mustache" (circumoral pallor) typical of scarlet fever.]] |
| | align="center" style="background:#f0f0f0;"|'''Comments'''
| | |
| | align="center" style="background:#f0f0f0;"|'''Contraindications'''
| | We heard you. '''Our native WikEM app is back!''' Download from your app store now ([http://apps.apple.com/us/app/wikem/id576405449 iOS] and [https://play.google.com/store/apps/details?id=wikem.chris Android]). |
| |-
| | |
| | Calcium-Channel Blockers||||||
| | [http://mediawiki.org MediaWiki] |
| |-
| | |
| | [[Diltiazem]]||*Bolus 0.25 mg/kg (average adult dose 20mg) over 2 min *If, after 15min 1st dose is tolerated but inadequate re-bolus 0.35 mg/kg *If patient responds start infusion at 5-15mg/hr or give PO dilt 30mg QID||*Preferred in patients with chronic lung such as [[Asthma]] and [[COPD]]Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011 May 10;342:d2549||#Decompensated heart failure #Preexcitation (especially in pediatrics) #*Significant hypotension
| | [http://apps.apple.com App] |
| |-
| | |
| | Beta-Blockers||||||
| | [https://apps.apple.com App] |
| |-
| | |
| | [[Metoprolol]]||*Bolus 2.5-5mg IVP over 2min q5min up to 3 doses *If patient responds orally load with 25-50mg||*Particularly useful when A-fib a/w exercise, after acute MI, or w/ thyrotoxicosis *Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for acute conversion if they do not have any relative contraindications.Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85||#COPD #Asthma #Decompensated heart failure #Hypotension
| | [http://apps.apple.com/us/app/wikem/id576405449 iOS] |
| |-
| | |
| | [[Esmolol]]||*Bolus 0.5 mg/kg over one minute, followed by 50 µg/kg/min *If, after 4min response is inadequate, re-bolus followed by infusion of 100 µg/kg/min *If, after 4min response is still inadequate, try final bolus followed by infusion of 150 µg/kg/min *If necessary, infusion can be increased to maximum of 200 µg/kg/min after another four minutes||*Use if unsure whether patient will tolerate a beta blocker since the duration of action is only 10 minutes||
| | [https://apps.apple.com/us/app/wikem/id576405449 https://play.google.com/store/apps/details?id=wikem.chris iOS] |
| |-
| |
| | Other||||||
| |
| |-
| |
| | [[Digoxin]]||||||
| |
| |-
| |
| | ||*0.25 mg IV q2hr up to 1.5 mg, then 0.125-0.25 mg PO or IV QD *Adjust dose in presence of renal failure, amiodarone, etc||*Consider as initial therapy for pts with LV dysfunction who: **Do not achieve rate control targets on beta blockers alone **Cannot tolerate addition of or increased doses of beta blocker due to decompensated CHF **Would have digoxin added anyway to improve CHF symptoms independent of A-fib *Consider as initial therapy in pts with severe hypotension *Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate *May take up to 6-8 hours to work||
| |
| |-
| |
| | [[Amiodarone]]||*Load 3-7 mg/kg IV over 30 min; then 1200 mg over 24hr via continuous infusion or in divided oral dosesKhan IA et al. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003 Jun;89(2-3):239-48.||*Consider for patients with decompensated heart failure or those with accessory pathways *2nd-line agent for chronic rate control when BBs and CCBs, alone, combined, or when used with digoxin, are ineffective||
| |
| |}
| |
